Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial

Sarah Brown(University of Leeds), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Avie‐Lee Tillotson(University of Leeds), Debbie Sherratt(University of Leeds), Charlotte Pawlyn(Royal Marsden NHS Foundation Trust), Martin Kaiser(Royal Marsden NHS Foundation Trust), Gareth J. Morgan(Hywel Dda University Health Board), Louise Flanagan(University of Leeds), Eric Low(Myeloma UK), Faith E. Davies(NYU Langone Health)
Clinical Lymphoma Myeloma & Leukemia
December 4, 2020
10.1016/j.clml.2020.11.019
Cited by 22

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k